REGENXBIO, Inc. (RGNX)
7.43
+0.01
(+0.13%)
USD |
NASDAQ |
Oct 02, 16:00
7.54
+0.11
(+1.48%)
After-Hours: 20:00
REGENXBIO Gross Profit Margin (Quarterly) : 95.56% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 95.56% |
| March 31, 2026 | -133.6% |
| December 31, 2025 | 67.71% |
| September 30, 2025 | 67.68% |
| June 30, 2025 | 57.33% |
| March 31, 2025 | 91.70% |
| December 31, 2024 | 51.25% |
| September 30, 2024 | 32.44% |
| June 30, 2024 | 34.38% |
| March 31, 2024 | 45.83% |
| December 31, 2023 | 29.89% |
| September 30, 2023 | 42.04% |
| June 30, 2023 | 30.37% |
| March 31, 2023 | 56.68% |
| December 31, 2022 | 46.06% |
| September 30, 2022 | 37.22% |
| June 30, 2022 | 52.24% |
| March 31, 2022 | 59.01% |
| December 31, 2021 | 93.56% |
| September 30, 2021 | 44.97% |
| June 30, 2021 | 45.45% |
| March 31, 2021 | 64.10% |
| December 31, 2020 | 42.35% |
| September 30, 2020 | 80.25% |
| Date | Value |
|---|---|
| June 30, 2020 | 58.86% |
| March 31, 2020 | 69.38% |
| December 31, 2019 | 51.44% |
| September 30, 2019 | 70.34% |
| June 30, 2019 | 53.36% |
| March 31, 2019 | -85.86% |
| December 31, 2018 | 89.81% |
| September 30, 2018 | 72.52% |
| June 30, 2018 | 88.09% |
| March 31, 2018 | 97.55% |
| December 31, 2017 | 83.28% |
| September 30, 2017 | 22.46% |
| June 30, 2017 | 69.22% |
| March 31, 2017 | -41.76% |
| December 31, 2016 | 80.54% |
| September 30, 2016 | -28.00% |
| June 30, 2016 | 79.03% |
| March 31, 2016 | 75.57% |
| December 31, 2015 | 80.12% |
| September 30, 2015 | 77.46% |
| June 30, 2015 | 77.26% |
| March 31, 2015 | 91.77% |
| March 31, 2014 | 81.44% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| AbbVie, Inc. | 74.71% |
| United Therapeutics Corp. | 87.30% |
| Ardelyx, Inc. | 94.74% |
| Biomea Fusion, Inc. | -- |
| RenovoRx, Inc. | 84.27% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -172.1% |
| Return on Assets | -42.93% |
| Return on Invested Capital | -52.52% |
| Profit Margin (Quarterly) | 21.02% |
| Operating Margin (Quarterly) | 27.09% |
| Return on Net Operating Assets | -97.50% |